DaVita Healthcare Partners delivers dialysis services to patients with chronic kidney failure and end stage renal disease. The company was founded in 1994 and is based in Denver, Colorado.
DVA Price Forecast Based on DCF Valuation
DCF Fair Value Target:
We started the process of determining a valid price forecast for Davita Inc with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Davita Inc ranked in the 64th percentile in terms of potential gain offered. Specifically, our DCF analysis implies the stock is trading below its fair value by an estimated 72.17%. In terms of the factors that were most noteworthy in this DCF analysis for DVA, they are:
The stock's equity weight, or the proportion of capital from equity relative to debt, is 57. Its equity weight surpasses that of merely 13.34% of free cash flow generating stocks in the Healthcare sector.
Davita Inc's weighted average cost of capital (WACC) is 7%; for context, that number is higher than merely 2.56% of tickers in our DCF set.
Terminal Growth Rate in Free Cash Flow
Return Relative to Current Share Price
For other companies in the Healthcare that have a similar discounted cashflow valuation profile (and ensuing price forecasts) as DVA, try ANTM, DGX, NVO, MCK, and FMS.
Market Dynamics: With a substantial CAGR over the forecast period, the global demand for hemodialysis and peritoneal dialysis is likely to expand. Based on major segmentations, the main objective of this report is to analyze, identify, identify and assess the global
Diagnostics innovator Renalytix AI plc and dialysis giant Davita Inc. partnered to develop a program to identify individuals with early-stage kidney disease and improve outcomes for the 37 million Americans with chronic kidney disease (CKD). The companies plan to launch the collaborative effort in three cities in 2021 to build a diverse, real-world evidence dataset as a base for moving forward.
Data bridge Market research provides a report in which the Medical - Social Working Services market drivers and regulations are derived from a famous SWOT analysis technique. We’ve taken up their organization profiles to really understand those key gamers
Introduction My wealth management is essentially based on two principles or goals. The first goal should always be to preserve current wealth. Only the second step should be to increase wealth. So look first at the risk, then at the opportunities. I have been looking at Fresenius Medical Care (FMS)...
The European View on Seeking Alpha | January 5, 2021
DaVita Inc. (NYSE: DVA ) is focused on dialysis, which means that it is unlikely to get much of a boost from a reacceleration in volumes within health care, of which Tenet Healthcare Corp (NYSE: THC ) is a key beneficiary, according to BofA Securities. The Health Care Analyst: Kevin Fischbeck downgraded DaVita from Buy to Neutral and raised the price target from $122 to $127. In a separate note, the analyst upgraded Tenet Healthcare from Neutral to Buy and raised the price target from $45 to $50. The Health Care Thesis: The Medicare rate environment is positive, and DaVita should continue to exhibit strong cost … Full story available on Benzinga.com